Yahoo
NSE - Delayed Quote INR

Dr. Lal PathLabs Limited (LALPATHLAB.NS)

1,906.40 -5.30 (-0.28%)
At close: October 30 at 3:29:56 PM GMT+5:30
Chart Range Bar
Loading chart for LALPATHLAB.NS
  • Previous Close 1,911.70
  • Open 1,911.70
  • Bid --
  • Ask --
  • Day's Range 1,886.00 - 1,958.00
  • 52 Week Range 1,272.60 - 2,038.60
  • Volume 282,549
  • Avg. Volume 281,218
  • Market Cap (intraday) 318.771B
  • Beta (5Y Monthly) 0.16
  • PE Ratio (TTM) 58.84
  • EPS (TTM) 32.40
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield 20.00 (1.05%)
  • Ex-Dividend Date Jul 30, 2026
  • 1y Target Est 2,018.08

Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.

www.lalpathlabs.com

5,206

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

LALPATHLAB.NS
29.56%
S&P BSE SENSEX (^BSESN)
12.63%

1-Year Return

LALPATHLAB.NS
24.63%
S&P BSE SENSEX (^BSESN)
11.78%

3-Year Return

LALPATHLAB.NS
65.69%
S&P BSE SENSEX (^BSESN)
16.14%

5-Year Return

LALPATHLAB.NS
12.79%
S&P BSE SENSEX (^BSESN)
25.55%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 7.98B
Earnings 1.7B
Profit Margin 21.25%

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

0
2B
4B
6B
14.0%
16.0%
18.0%
20.0%

Analyst Insights

View More

Analyst Price Targets

1,180.00 Low
2,018.08 Average
1,906.40 Current
2,380.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    18.75%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    28.91B

  • Net Income Avi to Common (ttm)

    5.42B

  • Diluted EPS (ttm)

    32.40

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    13.31B

  • Total Debt/Equity (mrq)

    7.83%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: